Aktiviteter
Forskningen i Klinik for Hjerteforskning spænder over Egen-initierede studier til Nationale kardiologiske studier og Clinical trails.
Egen-initierede studier
- Testing in coronary artery disease II - Laust Dupont Rasmussen
- Betydning af social ulighed og utryghed for udvikling af kardiovaskulære og metaboliske risikofaktorer hos unge voksne – Mia Klinkvort Kempel
- Management of patients with suspected stable coronary artery disease – Louise Bjerking
- Coronary flow and plaque characteristics in kidney transplant candidates – Jonathan Nørtoft Dahl
- Effect of including circulating proteins and genetic information in predictive risk models of obstructive coronary artery disease – Gitte Stokvad Brix
- Opportunistisk screening for osteoporose – et dansk multicenter studie - Andia Cheneymann
- Dan-NICAD 3 - Danish Study of non-invasive diagnostic testing in coronary artery disease III – Simon Winther
- Association of subjective social status in adolescense and obesity in adulthood – a substudy from the VestLiv cohort - Louise Stampe
- Association of physical activity in adolescense and cardio-metabolic-inflammatory risk markers in adulthood – a clinical substudy on sampled participants from the VestLiv Cohort - Stine Malling Søndergaard
- Significance of socio-economic status, BMI, and sex in self-reported height and weight versus measured height and weight - a clinical substudy on sampled participants from the VestLiv Cohort – Vibeke Lynggaard
- Optimal medicinsk behandling versus PCI for symptombyrde og perfusionsbedring malt på Rb-PET og Seattle Angina Questionnaire – a Dan-NICAD 2 substudy – Laust Dupont Rasmussen
- Plaque analyses and comparisons within Dan-NICAD 1 + 2 – Laust Dupont Rasmussen og Jonathan Nørtoft Dahl
Nationale kardiologiske studier (ikke firmasponsorerede)
- Dan-HEART – Hydralazine-ISDN and/or Metformin in Patients With Chronic Heart Failure and/or Diabetes or Insulin Resistance – A randomized, double-blind, placebo controlled study – coordinating site: AUH and Rigshospitalet
- Dan-BLOCK – Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction – coordinating site: Bispebjerg and Frederiksberg Hospital
- ARTESIA – Apixaban for the Reduction of Thrombo-Embolism in patients with device-detected Sub-clInical Atrial fibrillation – coordinating site: Population Health Research Institute, Hamilton, Canada
Clinical trials
- OutcoMes by reducing triglycederides IN patiENts with diabeTes – sponsor: KOWA
- AEGIS-II – A phase III, multicenter, Double-blind, Randomized, Placebo-controleld, Parallel-group Study to Investigate the Efficacy and safety of CSL112 (apolipoprotein A-I) in subject with Acute Coronary Syndrome – sponsor: CSL Behring LLC
- SELECT – Semaglutide effects on cardiovascular outcomes in people with overweight or obesity and established CV disease – sponsor: Novo Nordisk
- ORION-8 – A long term extension trial of the phase III lipid-lowering trials to assess the effect of long term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL – sponsor: Novartis
- VESALIUS – A double-blind, randomized, placebo-controlled, multicenter study to evaluate the impact of evolocumab on major cardiovascular events in patients at high cardiovascular risk without prior myocardial infarction or stroke – sponsor: Amgen
- FINEARTS-HF – A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥ 40% (LVEF ≥ 40%) – sponsor: Bayer
- SOLANO – A randomized, parallel, double-blind, placebo-controlled phase Iib study to assess the safety, tolerability and efficacy of AZD8233 (PCSK9-targeted ASO) treatment in participants with hyperlipidaemia – sponsor: AstraZeneca
- ZEUS – Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systematic inflammation – sponsor: Novo Nordisk
- SOS-AMI – Selatogrel Outcome Study in suspected Acute Myocardial Infarction – sponsor Idorsia
- VICTORION-2-PREVENT – A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease – sponsor Novartis